These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 31526225)

  • 21. Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial.
    Pepin S; Nicolas JF; Szymanski H; Leroux-Roels I; Schaum T; Bonten M; Icardi G; Shrestha A; Tabar C;
    Hum Vaccin Immunother; 2021 Dec; 17(12):5475-5486. PubMed ID: 34714720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women.
    Munoz FM; Jackson LA; Swamy GK; Edwards KM; Frey SE; Stephens I; Ault K; Winokur P; Petrie CR; Wolff M; Patel SM; Keitel WA
    Vaccine; 2018 Dec; 36(52):8054-8061. PubMed ID: 30416018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9-59 years: A randomized, double-blind, controlled, phase IV clinical trial.
    Gao Y; Yang X; Li X; Chen H; Li Y; Tan X; Yu D; Feng T; Zhou S; Lei S; Zhao C; Wang J; Guan Q
    Vaccine; 2024 Aug; 42(21):126182. PubMed ID: 39116486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.
    Pepin S; Dupuy M; Borja-Tabora CFC; Montellano M; Bravo L; Santos J; de Castro JA; Rivera-Medina DM; Cutland C; Ariza M; Diez-Domingo J; Gonzalez CD; Martinón-Torres F; Papadopoulou-Alataki E; Theodoriadou M; Kazek-Duret MP; Gurunathan S; De Bruijn I;
    Vaccine; 2019 Mar; 37(13):1876-1884. PubMed ID: 30558818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of a quadrivalent inactivated subunit non-adjuvanted influenza vaccine: A randomized, double-blind, active-controlled phase 1 clinical trial.
    Wang Y; Zhang Y; Wu H; Huang L; Yu H; Xie Z; Zhang H; Zhang W; Chen X; Zhang H; Zhang H; Jia C; Xia S; Wang S
    Vaccine; 2021 Jun; 39(29):3871-3878. PubMed ID: 34088505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.
    Ofori-Anyinam O; Leroux-Roels G; Drame M; Aerssens A; Maes C; Amanullah A; Schuind A; Li P; Jain VK; Innis BL
    Vaccine; 2017 Nov; 35(46):6321-6328. PubMed ID: 28987445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influenza vaccination of pregnant women and protection of their infants.
    Madhi SA; Cutland CL; Kuwanda L; Weinberg A; Hugo A; Jones S; Adrian PV; van Niekerk N; Treurnicht F; Ortiz JR; Venter M; Violari A; Neuzil KM; Simões EA; Klugman KP; Nunes MC;
    N Engl J Med; 2014 Sep; 371(10):918-31. PubMed ID: 25184864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults.
    Chahine EB
    Ann Pharmacother; 2021 Jan; 55(1):89-97. PubMed ID: 32578447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial.
    Nunes MC; Cutland CL; Moultrie A; Jones S; Ortiz JR; Neuzil KM; Klugman KP; Simões EAF; Weinberg A; Madhi SA;
    Lancet HIV; 2020 Feb; 7(2):e91-e103. PubMed ID: 31911146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial.
    Huang X; Fan T; Li L; Nian X; Zhang J; Gao X; Zhao W; Chen W; Zhang Z; Yao Z; Han X; Shi J; Wang Y; Bian H; Shi N; Li X; Duan K; Li G; Yang X
    Hum Vaccin Immunother; 2022 Nov; 18(5):2079924. PubMed ID: 35714276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine.
    Montalban C; Montellano MB; Santos J; Lavis N
    Hum Vaccin Immunother; 2018 Mar; 14(3):593-595. PubMed ID: 28933626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children.
    Claeys C; Chandrasekaran V; García-Sicilia J; Prymula R; Díez-Domingo J; Brzostek J; Marès-Bermúdez J; Martinón-Torres F; Pollard AJ; Růžková R; Carmona Martinez A; Ulied A; Miranda Valdivieso M; Faust SN; Snape MD; Friel D; Ollinger T; Soni J; Schuind A; Li P; Innis BL; Jain VK
    Pediatr Infect Dis J; 2019 Feb; 38(2):203-210. PubMed ID: 30325891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
    Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ
    Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial.
    Ortiz JR; Spearman PW; Goepfert PA; Cross K; Buddy Creech C; Chen WH; Parker S; Overton ET; Dickey M; Logan HL; Wegel A; Neuzil KM
    Vaccine; 2022 May; 40(23):3253-3262. PubMed ID: 35465983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil.
    Zerbini CA; Ribeiro Dos Santos R; Jose Nunes M; Soni J; Li P; Jain VK; Ofori-Anyinam O
    Braz J Infect Dis; 2017; 21(1):63-70. PubMed ID: 27912069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age: A Randomized Controlled Clinical Trial.
    Robertson CA; Mercer M; Selmani A; Klein NP; Jeanfreau R; Greenberg DP
    Pediatr Infect Dis J; 2019 Mar; 38(3):323-328. PubMed ID: 30395011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial.
    Tapia MD; Sow SO; Tamboura B; Tégueté I; Pasetti MF; Kodio M; Onwuchekwa U; Tennant SM; Blackwelder WC; Coulibaly F; Traoré A; Keita AM; Haidara FC; Diallo F; Doumbia M; Sanogo D; DeMatt E; Schluterman NH; Buchwald A; Kotloff KL; Chen WH; Orenstein EW; Orenstein LAV; Villanueva J; Bresee J; Treanor J; Levine MM
    Lancet Infect Dis; 2016 Sep; 16(9):1026-1035. PubMed ID: 27261067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Seroresponse to Inactivated and Recombinant Influenza Vaccines Among Maintenance Hemodialysis Patients.
    Manley HJ; Lacson EK; Aweh G; Chen Li N; Weiner DE; Miskulin DC; Hsu CM; Kapoian T; Hayney MS; Meyer KB; Johnson DS
    Am J Kidney Dis; 2022 Sep; 80(3):309-318. PubMed ID: 35288216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season.
    Gandhi-Banga S; Chabanon AL; Eymin C; Caroe T; Butler K; Moureau A
    Hum Vaccin Immunother; 2019; 15(9):2154-2158. PubMed ID: 30897026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.